Literature DB >> 27766683

What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: Balancing Benefits and Safety with Intravenous Iron Treatment.

M Alan Brookhart1,2, Xiaojuan Li1,3, Abhijit V Kshirsagar3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27766683      PMCID： PMC5393346          DOI： 10.1111/sdi.12550

Source DB:  PubMed          Journal:  Semin Dial        ISSN： 0894-0959            Impact factor:   3.455


× No keyword cloud information.
  24 in total

Review 1.  Evolving statistical methods to facilitate evaluation of the causal association between erythropoiesis-stimulating agent dose and mortality in nonexperimental research: strengths and limitations.

Authors:  Brian D Bradbury; M Alan Brookhart; Wolfgang C Winkelmayer; Cathy W Critchlow; Ryan D Kilpatrick; Marshall M Joffe; Harold I Feldman; John F Acquavella; Ouhong Wang; Kenneth J Rothman
Journal:  Am J Kidney Dis       Date:  2009-07-09       Impact factor: 8.860

Review 2.  Intravenous iron therapy in end-stage renal disease.

Authors:  Ursula C Brewster
Journal:  Semin Dial       Date:  2006 Jul-Aug       Impact factor: 3.455

Review 3.  Balance of Benefit and Risk in Intravenous Iron Treatment in Chronic Kidney Disease.

Authors:  Steven Fishbane
Journal:  Semin Nephrol       Date:  2016-03       Impact factor: 5.299

4.  Changing patterns of anemia management in US hemodialysis patients.

Authors:  Janet K Freburger; Leslie J Ng; Brian D Bradbury; Abhijit V Kshirsagar; M Alan Brookhart
Journal:  Am J Med       Date:  2012-09       Impact factor: 4.965

5.  Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration.

Authors:  J Parkkinen; L von Bonsdorff; S Peltonen; C Grönhagen-Riska; K Rosenlöf
Journal:  Nephrol Dial Transplant       Date:  2000-11       Impact factor: 5.992

Review 6.  Parenteral versus oral iron therapy for adults and children with chronic kidney disease.

Authors:  Jumana Albaramki; Elisabeth M Hodson; Jonathan C Craig; Angela C Webster
Journal:  Cochrane Database Syst Rev       Date:  2012-01-18

7.  Intravenous iron exposure and mortality in patients on hemodialysis.

Authors:  Dana C Miskulin; Navdeep Tangri; Karen Bandeen-Roche; Jing Zhou; Aidan McDermott; Klemens B Meyer; Patti L Ephraim; Wieneke M Michels; Bernard G Jaar; Deidra C Crews; Julia J Scialla; Stephen M Sozio; Tariq Shafi; Albert W Wu; Courtney Cook; L Ebony Boulware
Journal:  Clin J Am Soc Nephrol       Date:  2014-10-15       Impact factor: 8.237

8.  The comparative short-term effectiveness of iron dosing and formulations in US hemodialysis patients.

Authors:  Abhijit V Kshirsagar; Janet K Freburger; Alan R Ellis; Lily Wang; Wolfgang C Winkelmayer; M Alan Brookhart
Journal:  Am J Med       Date:  2013-04-15       Impact factor: 4.965

9.  Comparative Effectiveness of Iron and Erythropoiesis-Stimulating Agent Dosing on Health-Related Quality of Life in Patients Receiving Hemodialysis.

Authors:  Janet K Freburger; Alan R Ellis; Lily Wang; Anne M Butler; Abhijit V Kshirsagar; Wolfgang C Winkelmayer; M Alan Brookhart
Journal:  Am J Kidney Dis       Date:  2015-10-23       Impact factor: 8.860

10.  Trends in anemia management in US hemodialysis patients 2004-2010.

Authors:  Dana C Miskulin; Jing Zhou; Navdeep Tangri; Karen Bandeen-Roche; Courtney Cook; Patti L Ephraim; Deidra C Crews; Julia J Scialla; Stephen M Sozio; Tariq Shafi; Bernard G Jaar; L Ebony Boulware
Journal:  BMC Nephrol       Date:  2013-12-01       Impact factor: 2.388
View more
  1 in total

Review 1.  Safety of intravenous iron in hemodialysis patients.

Authors:  Xiaojuan Li; Abhijit V Kshirsagar; M Alan Brookhart
Journal:  Hemodial Int       Date:  2017-04-03       Impact factor: 1.812
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.